Roche Holding AG got US Food and Drug Administration approval for expansion of lung cancer therapy Alecensa’s label to include adjuvant treatment of early-stage, anaplastic lymphoma kinase (ALK)-posi
Eli Lilly & Co. ’s $8bn acquisition of Loxo Oncology Inc. in January is looking more like a win as selpercatinib (LOXO-292) posted Phase I/II data in RET fusion-positive non-small cell lung cancer (
Although some investors are disappointed by the lack of a straightforward buyout, market analysts agree that Loxo Oncology Inc. achieved victory in multiple ways under an agreement with Bayer AG
[ Editors' note : For sortable and searchable tables of US and international approvals and clearances, check out our Approvals Tracker .] US FDA cleared 299 510(k)s in May, the highest monthly cle